Dunkelman H, Earl H M, Twelves C
Department of Radiotherapy and Oncology, University College Hospital, London, UK.
Cancer Chemother Pharmacol. 1991;27(4):329-30. doi: 10.1007/BF00685121.
We report on two patients with non-Hodgkin's lymphoma (NHL) who developed reversible, short-lived neurological deficit following intrathecal (i.t.) chemotherapy. One patient received i.t. methotrexate for treatment of meningeal disease, and the other received i.t. methotrexate with cytosine arabinoside (ara-C) and hydrocortisone as central nervous system (CNS) prophylaxis. Although transient paresis following i.t. chemotherapy has previously been reported, it has been attributed to the preservatives contained in the diluents. Our two patients, however, received preservative-free solutions.
我们报告了两名非霍奇金淋巴瘤（NHL）患者，他们在鞘内注射（i.t.）化疗后出现了可逆的、短暂的神经功能缺损。一名患者接受鞘内注射甲氨蝶呤治疗脑膜疾病，另一名患者接受鞘内注射甲氨蝶呤联合阿糖胞苷（ara-C）和氢化可的松作为中枢神经系统（CNS）预防用药。虽然此前已有鞘内注射化疗后出现短暂性轻瘫的报道，但一直认为这是由于稀释剂中所含的防腐剂所致。然而，我们的两名患者接受的是不含防腐剂的溶液。
